Vivacitas is a private clinical-stage biopharmaceutical company focused on developing next-generation oncological therapies and re-designing current treatments that, even when efficacious, are overshadowed by their toxic effects on patients. Vivacitas’ lead compound, AR-67, is a Camptothecin-based technology that has already shown an attractive clinical profile in Phase I and II studies, wherein patients with solid tumors experienced less toxicity with a positive efficacy trend. Through an enduring spirit, Vivacitas continues to apply clarity, tenacity and vision in our fight against aggressive cancers and our pursuit of new treatment options for patients and their families worldwide.